2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
2seventy bio, Inc. (TSVT)
Company Research
Source: Business Wire
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology.The program is based on the original research agreement, established in 2019, which focused on a gene editing therapy for people with Hemophilia A. 2seventy bio will focus exclusively on the commercialization and continued development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with Bristol M
Show less
Read more
Impact Snapshot
Event Time:
TSVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSVT alerts
High impacting 2seventy bio, Inc. news events
Weekly update
A roundup of the hottest topics
TSVT
News
- 2seventy bio, Inc. (NASDAQ: TSVT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
- 2seventy bio, Inc. (NASDAQ: TSVT) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $2.00 price target on the stock, down previously from $5.00.MarketBeat
- 2seventy bio to Participate in Upcoming Investor ConferencesBusiness Wire
- 2seventy bio, Inc. (NASDAQ: TSVT) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.MarketBeat
- 2seventy bio, Inc. (NASDAQ: TSVT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
TSVT
Earnings
- 5/8/24 - Miss
TSVT
Sec Filings
- 6/26/24 - Form 8-K
- 6/12/24 - Form 4
- 6/12/24 - Form 4
- TSVT's page on the SEC website